Headquartered in San Diego, California, Pfenex Inc., is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars.
According to company’s website, Pfenex is utilizing Pf?nex Expression Technology to build a portfolio of biosimilar molecules. Pfenex does not want to repeat the innovator’s protein expression and bioprocess strategy that may have been developed more than 20 years ago. The company applies its parallel processing, toolbox approach to strain development to arrive at a highly advantaged expression strain and bioprocess.
Capitalizing on the cost effectiveness of the Pfenex protein expression Technology-based processes and the proven ability to rapidly identify a robust production strain, Pfenex is trying to become a global leader in biosimilar development.
Pfenex currently has three biosimilar molecules in development. As you can see from the below diagram, the company is co-developing an interferon beta-1b biosimilar, plus Human Growth Hormone (hGH) and Granulocyte Colony-Stimulating Factor (G-CSF) biosimilars are partnered with other companies.
The company was selected as one of 2011’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry and they are currently seeking co-development partners on these, and on other new biosimilar programs.